Gastroparesis is a chronic gastric motility disorder defined by delayed gastric emptying in the absence of mechanical obstruction, with cardinal symptoms of nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. [1-2] The most common etiologies are idiopathic (largest group at tertiary centers), diabetic, and postsurgical, with less common causes including post-viral, medication-induced (opioids, GLP-1 agonists), neurodegenerative (Parkinson's), connective tissue disorders (scleroderma), and paraneoplastic syndromes. [3-5]
1. History
- Nausea — nearly universal; most troubling symptom in >40% of patients; correlates with severity of gastric emptying delay [6]
- Vomiting — often relieves nausea; may contain partly digested food (delayed >1 hour after meals); quantify frequency and volume [7]
- Timing — symptoms worsen postprandially; ask about early satiety, postprandial fullness, bloating
- Abdominal pain — increasingly recognized as a prominent feature, especially in idiopathic gastroparesis; often the symptom prompting evaluation [3]
- Weight changes — weight loss from poor intake vs. paradoxical weight gain (especially type 2 diabetes) [3]
- Triggers — large meals, high-fat/high-fiber foods, carbonated beverages
- Progression — acute exacerbation vs. chronic baseline; prior episodes and hospitalizations
- Important negatives — hematemesis, melena, dysphagia, fever, jaundice (suggest alternative diagnoses)
2. Alarm Features
- Intractable vomiting with inability to tolerate oral intake or medications
- Signs of dehydration — orthostasis, tachycardia, oliguria
- Significant weight loss (>5–10% body weight) or malnutrition
- Hematemesis — Mallory-Weiss tear from forceful vomiting, or alternative pathology
- Severe abdominal pain disproportionate to exam — consider SBO, mesenteric ischemia, perforation
- New-onset symptoms in older adults — raises concern for malignancy or gastric outlet obstruction
- Diabetic ketoacidosis or severe hyperglycemia in diabetic patients
- Electrolyte derangements — hypokalemia, metabolic alkalosis from protracted vomiting
- Succussion splash on exam — suggests significant gastric retention or outlet obstruction [4]
3. Medications
Medications that delay gastric emptying (review and discontinue if possible):
- Opioids — major contributor; cessation recommended [2]
- GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) [2][5]
- Anticholinergics, calcium channel blockers, clonidine, dopamine agonists, lithium
Treatments
Contraindicated/caution: Avoid opioids (worsen motility), anticholinergics, and cannabis (may cause hyperemesis). Nortriptyline showed no benefit in a RCT and had higher discontinuation rates. [1]
4. Diet
Per ACG and AGA guidelines, dietary modification is first-line therapy and should be initiated before or alongside pharmacologic treatment: [2-3][11]
- Small particle diet — soft foods, easily chewed into small pieces; shown in RCT to reduce symptoms and improve gastric emptying in diabetic gastroparesis [1][3]
- Low-fat, low-residue — fat delays gastric emptying; insoluble fiber forms bezoars
- Frequent small meals (4–6/day) rather than 3 large meals
- Increase liquid-containing meals — soups, smoothies, nutritional supplements (liquids empty more easily)
- Avoid fatty, spicy, acidic, and high-fiber foods [8]
- Hydration — critical during acute exacerbations; IV fluids if unable to tolerate PO
- Soluble fiber (low viscosity) may be tolerated in mild-moderate disease [12]
- High-fat liquid meals may be reasonably tolerated and can supplement caloric intake [12]
- Diabetic patients — optimize glycemic control; hyperglycemia independently delays gastric emptying [2]
5. Review of Systems
- GI: Nausea, vomiting, early satiety, bloating, postprandial fullness, abdominal pain, GERD symptoms, constipation (common overlap with IBS)
- Constitutional: Weight loss, fatigue, malnutrition signs
- Endocrine: Polyuria/polydipsia (uncontrolled diabetes), cold intolerance (hypothyroidism)
- Neurologic: Peripheral neuropathy, autonomic symptoms (orthostasis, urinary retention, anhidrosis)
- Psychiatric: Depression, anxiety — significantly associated with symptom severity and healthcare utilization [13]
- Rheumatologic: Skin tightening, Raynaud's (scleroderma), dry eyes/mouth
6. Collateral History and Family History
- Collateral: Medication compliance (especially insulin/diabetes meds), actual dietary intake, substance use (cannabis — cannabinoid hyperemesis syndrome is a key mimic), opioid use, alcohol use
- Family history: Diabetes mellitus, autoimmune conditions, connective tissue disorders
- Social context: Depression, anxiety, eating disorders (avoidant/restrictive food intake disorder is frequent in gastroparesis), functional status, ability to prepare appropriate meals [1]
7. Risk Factors
- Diabetes mellitus (type 1 and type 2) — most common identifiable cause; poor glycemic control is a risk factor [3]
- Female sex — prevalence ~4× higher in women (37.8 vs. 9.6 per 100,000) [4]
- Prior gastric/abdominal surgery — vagal nerve injury (fundoplication, bariatric surgery)
- Post-viral — preceding viral illness (CMV, EBV, norovirus)
- Medications — opioids, GLP-1 agonists [2][5]
- Connective tissue disorders — scleroderma, amyloidosis
- Neurodegenerative disease — Parkinson's disease
- Younger age, Black race, lower income — independently associated with ED visits and hospitalizations [13]
- Cannabis use, narcotic use, depression — associated with higher healthcare utilization [13]
8. Differential Diagnosis
- Gastric outlet obstruction — peptic ulcer disease, malignancy; bilious vomiting suggests distal obstruction [7]
- Cyclic vomiting syndrome — episodic pattern with symptom-free intervals; younger patients
- Cannabinoid hyperemesis syndrome — compulsive hot bathing, cannabis use; haloperidol often effective [9]
- Functional dyspepsia — significant symptom overlap; normal gastric emptying in 70–80%; may exist on same spectrum [6][14]
- Small bowel obstruction — bilious vomiting, distension, absent bowel sounds
- Superior mesenteric artery syndrome — postprandial pain, weight loss
- Median arcuate ligament syndrome — epigastric bruit, postprandial pain [4]
- Eating disorders (anorexia/bulimia) — vomiting during or soon after meals [7]
- Rumination syndrome — effortless regurgitation of recently ingested food
- Adrenal insufficiency — nausea, vomiting, hyperkalemia, metabolic acidosis [4]
- Hypothyroidism — can cause delayed gastric emptying
- Increased intracranial pressure — projectile vomiting, headache, papilledema [7]
9. Past Medical History
- Diabetes — type, duration, HbA1c, complications (neuropathy, retinopathy, nephropathy)
- Prior abdominal surgeries — fundoplication, cholecystectomy, bariatric surgery, vagotomy
- Previous episodes of gastroparesis flares, ED visits, hospitalizations (39% had prior ED visits, 23% had hospitalizations in one cohort) [13]
- Autoimmune/connective tissue disease
- Psychiatric comorbidities — depression and anxiety are independently associated with worse outcomes [13]
- Nutritional support history — prior tube feeds, TPN, jejunostomy
10. Physical Exam
- Vitals: Tachycardia, orthostatic hypotension (dehydration), fever (suggests alternative diagnosis)
- General: Cachexia, signs of malnutrition, dehydration (dry mucous membranes, poor skin turgor)
- Abdomen:
- Succussion splash — fluid sloshing >3 hours after eating suggests significant gastric retention [4]
- Distension, tenderness (usually mild/diffuse; focal peritoneal signs suggest alternative pathology)
- Absent/hypoactive bowel sounds
- Epigastric bruit — consider celiac artery compression/median arcuate ligament syndrome [4]
- Skin: Digital ulcers, telangiectasia (scleroderma), acanthosis nigricans (insulin resistance) [4]
- Neurologic: Peripheral neuropathy (stocking-glove distribution), autonomic dysfunction signs
- Lymph nodes/masses: Enlarged nodes or palpable mass raises concern for malignancy [4]
11. Lab Studies
12. Imaging
- Upper endoscopy (EGD) — required to exclude mechanical obstruction (pyloric stenosis, malignancy, ulcer disease) before diagnosing gastroparesis; food retention after overnight fast is suggestive but not diagnostic [1][6]
- CT abdomen — if concern for SBO, pancreatitis, malignancy, or SMA syndrome; not routinely needed
- RUQ ultrasound — if biliary pathology suspected
- Small bowel imaging — not routinely recommended but can be considered to rule out mechanical obstruction [6]
- Mesenteric duplex — only if median arcuate ligament syndrome suspected; not routine [6]
- Imaging is unnecessary for straightforward cases with known gastroparesis presenting with typical flare
13. Special Tests
Gastric emptying scintigraphy (GES) — gold standard: [1][6]
- 4-hour solid-phase study using Tc-99m labeled meal
- Diagnostic threshold: >10% gastric retention at 4 hours (or >60% at 2 hours)
- Must be performed off opioids and prokinetics (ideally 48–72 hours)
- Shorter studies (≤2 hours) miss a significant number of cases [2]
The following figure illustrates normal vs. delayed gastric emptying on scintigraphy:
- 13C-spirulina breath test (GEBT) — FDA-approved alternative; no radiation; good correlation with scintigraphy [6][17]
- Wireless motility capsule — FDA-approved but not endorsed by international consensus for gastroparesis diagnosis [6]
- Gastroparesis Cardinal Symptom Index (GCSI) — validated symptom severity tool [6]
- EndoFLIP — may characterize pyloric dysfunction and predict response to pyloromyotomy [1]
- Electrogastrography — research tool; not standard clinical practice
14. ECG
- Baseline ECG recommended before starting domperidone (QTc prolongation risk) [3][6]
- Check ECG if using metoclopramide in patients with cardiac risk factors
- Monitor for QTc prolongation with concurrent use of ondansetron, especially IV formulation
- Evaluate for electrolyte-related arrhythmias (hypokalemia, hypomagnesemia from vomiting)
15. Assessment
Severity stratification (guides management approach)
- Mild — symptoms partially controlled with dietary modification; able to maintain weight and nutrition on regular diet
- Moderate — partially controlled with prokinetics/antiemetics; some weight loss; occasional ED visits
- Severe/refractory — unable to maintain oral nutrition; frequent ED visits/hospitalizations; requires enteral/parenteral nutrition [4]
Key considerations:
- Symptoms overlap significantly with functional dyspepsia; gastric emptying testing may reclassify 37–42% of patients within a year [4]
- Abdominal pain is increasingly recognized and may be the predominant symptom in idiopathic gastroparesis [3]
- Complications include Mallory-Weiss tears, bezoar formation, aspiration, malnutrition, and electrolyte derangements [15]
16. Treatment Plan
Acute exacerbation (ED/inpatient)
- IV fluid resuscitation — correct dehydration and electrolyte abnormalities
- Antiemetics: Ondansetron 4 mg IV (most commonly used, 61% of ED visits); prochlorperazine 5–10 mg IV; promethazine 12.5–25 mg IV/IM [9]
- Prokinetics: Metoclopramide 10 mg IV; erythromycin 3 mg/kg IV q8h (acute use, rapid tachyphylaxis) [1]
- Haloperidol 5 mg IV — small RCT showed significant pain/nausea reduction in acute gastroparesis exacerbation in the ED, though ACG does not recommend routine use [1]
- Glucose control in diabetic patients — insulin drip if needed
- NPO initially → advance to clear liquids → gastroparesis diet as tolerated
- Avoid opioids for pain management; consider acetaminophen, low-dose gabapentin
Chronic management
- Dietary modification — small particle, low-fat, low-residue diet (first-line) [2-3]
- Metoclopramide 5–10 mg TID before meals (limit ≤12 weeks per Beers Criteria; risk of TD ~0.1% per 1000 patient-years) [3][8]
- Erythromycin 50–100 mg QID before meals and at bedtime (short course) [8]
- Antiemetics PRN — ondansetron, granisetron patch, prochlorperazine [2][4]
- Refractory cases: Domperidone (FDA IND), G-POEM (endoscopic pyloromyotomy), gastric electrical stimulation (HUD), venting gastrostomy, feeding jejunostomy [1]
- Nutritional support escalation: Oral → jejunal enteral nutrition → parenteral nutrition (last resort) [1]
17. Disposition
Admission criteria: [9][15]
- Intractable vomiting unresponsive to ED treatment
- Severe dehydration or electrolyte derangements requiring IV correction
- Inability to tolerate oral intake/medications
- Diabetic ketoacidosis or severe hyperglycemia
- Concern for alternative surgical diagnosis
- Malnutrition requiring nutritional support initiation
- Mean admission rate for gastroparesis ED visits: ~25%; mean LOS: 5.8 days [9]
Discharge criteria
- Tolerating oral liquids/soft diet
- Electrolytes corrected
- Nausea/vomiting controlled with oral medications
- Adequate outpatient follow-up arranged
- Able to maintain hydration
Specialist consultation triggers
- Refractory symptoms despite optimized medical therapy → GI/motility specialist
- Need for enteral access (jejunostomy) or consideration of G-POEM/GES
- Nutritional failure → nutrition support team
- Suspected surgical pathology → surgery
18. Follow Up / Return Precautions
Follow-up timing
- GI follow-up within 1–2 weeks after ED visit or hospitalization
- PCP follow-up within 1 week for medication monitoring
- Reassess pharmacologic efficacy at 4–8 weeks [2]
- Dietitian referral for gastroparesis-specific dietary counseling
Return precautions — advise return for
- Inability to keep down liquids for >24 hours
- Bloody or coffee-ground emesis
- Severe abdominal pain or distension
- Fever >101°F (38.3°C)
- Signs of dehydration (dizziness, dark urine, no urine output)
- Chest pain or palpitations (especially if on QTc-prolonging medications)
Expected course
- Gastroparesis is a chronic, relapsing condition; symptom fluctuation is common
- Idiopathic gastroparesis may improve or resolve over time in some patients
- Diabetic gastroparesis tends to be more persistent and correlates with glycemic control
- A sizeable subset are high healthcare utilizers — younger age, Black race, lower income, higher nausea/vomiting scores, depression, and cannabis use are independently associated with recurrent ED visits [13]
References
1. ACG Clinical Guideline: Gastroparesis. — Camilleri M, Kuo B, Nguyen L, et al. The American Journal of Gastroenterology. 2022.
2. AGA Clinical Practice Guideline on Management of Gastroparesis. — Staller K, Parkman HP, Greer KB, et al. Gastroenterology. 2025.
3. Disorders of Gastric Motility. — Shin A. The Lancet. Gastroenterology & Hepatology. 2024.
4. AGA Clinical Practice Update on Management of Medically Refractory Gastroparesis: Expert Review. — Lacy BE, Tack J, Gyawali CP. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association. 2022.
5. Pharmacologic Treatments for Gastroparesis. — Camilleri M, Jencks KJ. Pharmacological Reviews. 2025.
6. Rome Foundation and International Neurogastroenterology and Motility Societies' Consensus on Idiopathic Gastroparesis. — Schol J, Huang IH, Carbone F, et al. The Lancet. Gastroenterology & Hepatology. 2025.
7. Evaluation and Treatment of Nausea and Vomiting in Adults. — Johns T, Lawrence E. American Family Physician. 2024.
8. Alternative Treatments to Selected Medications in the 2023 American Geriatrics Society Beers Criteria®. — Steinman MA. Journal of the American Geriatrics Society. 2025.
9. Presentations to United States Emergency Departments for Gastroparesis, Cyclic Vomiting, and Cannabinoid Hyperemesis Syndrome From 2016 to 2024. — Shalaby M, Moyer E, Buell KG, Bernard K, Gottlieb M. The American Journal of Emergency Medicine. 2025.
10. Diabetic Gastroparesis. — Camilleri M. The New England Journal of Medicine. 2007.
11. Dietary Interventions for Gastroparesis: A Systematic Review. — Eseonu D, Su T, Lee K, et al. Advances in Nutrition. 2022.
12. Gastroparesis and Its Nutritional Implications. — Kasem F, Franz A, Omer E. Current Gastroenterology Reports. 2025.
13. Characterization of Patients With Symptoms of Gastroparesis Having Frequent Emergency Department Visits and Hospitalizations. — Parkman HP, Xin Y, Wilson LA, et al. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association. 2025.
14. ACG and CAG Clinical Guideline: Management of Dyspepsia. — Moayyedi P, Lacy BE, Andrews CN, et al. The American Journal of Gastroenterology. 2017.
15. Gastroparesis in the Hospital Setting. — Rangan V, Ukleja A. Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition. 2021.
16. Disorders of gastric emptying. — Henry P. Parkman Yamada's Atlas of Gastroenterology. 2022.
17. Gastroparesis: A Turning Point in Understanding and Treatment. — Grover M, Farrugia G, Stanghellini V. Gut. 2019.